[
  {
    "ts": null,
    "headline": "Johnson & Johnson is the latest pharma giant to court Trump with new investment plans",
    "summary": "Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing footprint in the United States.",
    "url": "https://finnhub.io/api/news?id=61380143af7912ad9416c2eac76e3412432b20c8c15c3f858922b0007b2eab15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742582460,
      "headline": "Johnson & Johnson is the latest pharma giant to court Trump with new investment plans",
      "id": 133324404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing footprint in the United States.",
      "url": "https://finnhub.io/api/news?id=61380143af7912ad9416c2eac76e3412432b20c8c15c3f858922b0007b2eab15"
    }
  },
  {
    "ts": null,
    "headline": "Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz",
    "summary": "The major indexes were fractionally higher near noon, continuing yesterday’s rally after the Federal Reserve held its benchmark interest rate steady on Wednesday, though Chair Jerome Powell noted there is “high uncertainty” about the potential impact of the Trump administration’s policies. Some solid housing data also allayed some worries about the U.S. economy potentially approaching a recession. Looking to commodities, gold prices have surged to new record highs, surpassing the $3,000 per ounc",
    "url": "https://finnhub.io/api/news?id=7fa6ca959283b7097352611a10933f0e01fb711fd47dfaa95a70d74f17e7d526",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742573786,
      "headline": "Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz",
      "id": 133324231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The major indexes were fractionally higher near noon, continuing yesterday’s rally after the Federal Reserve held its benchmark interest rate steady on Wednesday, though Chair Jerome Powell noted there is “high uncertainty” about the potential impact of the Trump administration’s policies. Some solid housing data also allayed some worries about the U.S. economy potentially approaching a recession. Looking to commodities, gold prices have surged to new record highs, surpassing the $3,000 per ounc",
      "url": "https://finnhub.io/api/news?id=7fa6ca959283b7097352611a10933f0e01fb711fd47dfaa95a70d74f17e7d526"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly launches weight-loss drug Mounjaro in India, Reuters says",
    "summary": "Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous country grappling with increasing rates of obesity and diabetes, Reuters’ Rishika Sadam reports. Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at 4,375 rupees or $50.67 for a 5 mg vial and 3,500 rupees or $40.54 for a 2.5 mg vial, its lowest dose, the company told Reuters se",
    "url": "https://finnhub.io/api/news?id=5fc4065c0637a4a779d0e392373ff0789e228d888f64bea2be3b4f10e282c2e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742566627,
      "headline": "Eli Lilly launches weight-loss drug Mounjaro in India, Reuters says",
      "id": 133324406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous country grappling with increasing rates of obesity and diabetes, Reuters’ Rishika Sadam reports. Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at 4,375 rupees or $50.67 for a 5 mg vial and 3,500 rupees or $40.54 for a 2.5 mg vial, its lowest dose, the company told Reuters se",
      "url": "https://finnhub.io/api/news?id=5fc4065c0637a4a779d0e392373ff0789e228d888f64bea2be3b4f10e282c2e6"
    }
  },
  {
    "ts": null,
    "headline": "3 of Goldman Sachs' best investing tips for currently volatile markets",
    "summary": "Volatile times in markets require precision, Goldman Sachs reminds investors.",
    "url": "https://finnhub.io/api/news?id=53de6c4e268d53424f20d6ebfaf8653bf2f6cec39368f385d4a1f70b569e3b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742563852,
      "headline": "3 of Goldman Sachs' best investing tips for currently volatile markets",
      "id": 133311382,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Volatile times in markets require precision, Goldman Sachs reminds investors.",
      "url": "https://finnhub.io/api/news?id=53de6c4e268d53424f20d6ebfaf8653bf2f6cec39368f385d4a1f70b569e3b67"
    }
  },
  {
    "ts": null,
    "headline": "The Mag 7 Are Dead Money. 6 ‘Megacap’ Stocks to Buy Instead.",
    "summary": "There is a laundry list of companies that have market capitalizations of more than $100 billion that look like buys",
    "url": "https://finnhub.io/api/news?id=0548c136d9b80269a7aaddab1b74e42eb6f61fe3a7c95feac788790d4a4c0a86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742558940,
      "headline": "The Mag 7 Are Dead Money. 6 ‘Megacap’ Stocks to Buy Instead.",
      "id": 133324408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There is a laundry list of companies that have market capitalizations of more than $100 billion that look like buys",
      "url": "https://finnhub.io/api/news?id=0548c136d9b80269a7aaddab1b74e42eb6f61fe3a7c95feac788790d4a4c0a86"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Growth With Higher Margins",
    "summary": "Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth initiatives. Click for my LLY update.",
    "url": "https://finnhub.io/api/news?id=131e8bd65ebe26e291ed4b9e2725742ae31f77f0f1d602614da2cc3ea2cb6054",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742549936,
      "headline": "Eli Lilly: Growth With Higher Margins",
      "id": 133299835,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2062753995/image_2062753995.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth initiatives. Click for my LLY update.",
      "url": "https://finnhub.io/api/news?id=131e8bd65ebe26e291ed4b9e2725742ae31f77f0f1d602614da2cc3ea2cb6054"
    }
  },
  {
    "ts": null,
    "headline": "Artisan International Small-Mid Fund Q4 2024 Commentary",
    "summary": "The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=ce959c45d4864292677dbe6942cdf386a007596884e67c2425329eafef49eb93",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742545800,
      "headline": "Artisan International Small-Mid Fund Q4 2024 Commentary",
      "id": 133297913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149929948/image_2149929948.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=ce959c45d4864292677dbe6942cdf386a007596884e67c2425329eafef49eb93"
    }
  },
  {
    "ts": null,
    "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
    "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
    "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742541707,
      "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
      "id": 133297533,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
      "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    }
  }
]